Acceptor-engineering tailored type-I photosensitizer with aggregation-induced NIR-II emission for cancer multimodal phototheranostics

IF 10.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Science China Chemistry Pub Date : 2024-06-26 DOI:10.1007/s11426-024-1980-x

Jiangao Li, Niu Niu, Deliang Wang, Xue Liu, Yi Qin, Lei Wang, Ben Zhong Tang, Dong Wang

{"title":"Acceptor-engineering tailored type-I photosensitizer with aggregation-induced NIR-II emission for cancer multimodal phototheranostics","authors":"Jiangao Li, Niu Niu, Deliang Wang, Xue Liu, Yi Qin, Lei Wang, Ben Zhong Tang, Dong Wang","doi":"10.1007/s11426-024-1980-x","DOIUrl":null,"url":null,"abstract":"<p>Exploration of single molecular species synchronously featured by long excitation/emission wavelength, accurate diagnosis, and effective therapy, remains supremely appealing to implement high-performance cancer phototheranostics. However, those previously established phototheranostic agents are undiversified and stereotyped in terms of structural skeleton, and generally exhibit insufficient phototheranostic outcomes. Herein, we innovatively utilized indanone-condensed thiadiazolo[3,4-g]quinoxaline (ITQ) as electron acceptor to construct novel photosensitizer with second near-infrared (NIR-II) emission. Experimental study and theoretical calculation demonstrated that comparing with the counterparts constituting by widely employed NIR-II building block benzobisthiadiazole (BBTD) and 6,7-diphenylthiadiazoloquinoxaline (DPTQ), ITQ-based photosensitizer (TITQ) showed superior aggregation-induced emission (AIE) characteristics, much stronger type-I reactive oxygen species (ROS) production, and prominent photothermal conversion capacity. Furthermore, TITQ nanoparticles with excellent biocompatibility were capable of effectively accumulating in the tumor site and visualizing tumor through fluorescence-photoacoustic-photothermal trimodal imaging with highly spatiotemporal resolution, and completely eliminating tumor by type-I photodynamic-photothermal therapy.</p>","PeriodicalId":772,"journal":{"name":"Science China Chemistry","volume":null,"pages":null},"PeriodicalIF":10.4000,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science China Chemistry","FirstCategoryId":"1","ListUrlMain":"https://doi.org/10.1007/s11426-024-1980-x","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Exploration of single molecular species synchronously featured by long excitation/emission wavelength, accurate diagnosis, and effective therapy, remains supremely appealing to implement high-performance cancer phototheranostics. However, those previously established phototheranostic agents are undiversified and stereotyped in terms of structural skeleton, and generally exhibit insufficient phototheranostic outcomes. Herein, we innovatively utilized indanone-condensed thiadiazolo[3,4-g]quinoxaline (ITQ) as electron acceptor to construct novel photosensitizer with second near-infrared (NIR-II) emission. Experimental study and theoretical calculation demonstrated that comparing with the counterparts constituting by widely employed NIR-II building block benzobisthiadiazole (BBTD) and 6,7-diphenylthiadiazoloquinoxaline (DPTQ), ITQ-based photosensitizer (TITQ) showed superior aggregation-induced emission (AIE) characteristics, much stronger type-I reactive oxygen species (ROS) production, and prominent photothermal conversion capacity. Furthermore, TITQ nanoparticles with excellent biocompatibility were capable of effectively accumulating in the tumor site and visualizing tumor through fluorescence-photoacoustic-photothermal trimodal imaging with highly spatiotemporal resolution, and completely eliminating tumor by type-I photodynamic-photothermal therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

具有聚集诱导近红外-II 发射的受体工程定制 I 型光敏剂，用于癌症多模式光otheranostics

以长激发/发射波长、精确诊断和有效治疗为特点的单分子同步探索，对于实现高性能癌症光热疗法仍具有极大的吸引力。然而，以往已开发的光热抑制剂在结构骨架方面不够多样化和定型化，普遍存在光热抑制效果不佳的问题。在此，我们创新性地利用茚酮缩合噻二唑并[3,4-g]喹喔啉（ITQ）作为电子受体，构建了具有二次近红外（NIR-II）发射的新型光敏剂。实验研究和理论计算表明，与广泛应用的近红外-II结构单元苯并双噻二唑（BBTD）和6,7-二苯基噻二唑并喹喔啉（DPTQ）相比，基于ITQ的光敏剂（TITQ）表现出更优越的聚集诱导发射（AIE）特性、更强的I型活性氧（ROS）生成能力和更突出的光热转换能力。此外，TITQ 纳米颗粒具有良好的生物相容性，能够有效地在肿瘤部位聚集，通过高时空分辨率的荧光-光声-光热三模成像技术观察肿瘤，并通过 I 型光动力-光热疗法彻底消除肿瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Science China Chemistry CHEMISTRY, MULTIDISCIPLINARY-

CiteScore

14.40

自引率

7.30%

发文量

3787

审稿时长

2.2 months

期刊介绍： Science China Chemistry, co-sponsored by the Chinese Academy of Sciences and the National Natural Science Foundation of China and published by Science China Press, publishes high-quality original research in both basic and applied chemistry. Indexed by Science Citation Index, it is a premier academic journal in the field. Categories of articles include: Highlights. Brief summaries and scholarly comments on recent research achievements in any field of chemistry. Perspectives. Concise reports on thelatest chemistry trends of interest to scientists worldwide, including discussions of research breakthroughs and interpretations of important science and funding policies. Reviews. In-depth summaries of representative results and achievements of the past 5–10 years in selected topics based on or closely related to the research expertise of the authors, providing a thorough assessment of the significance, current status, and future research directions of the field.